United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

arabian ethicals co. switzerland - 10's blister - tablet - 500mg / tablet - infections-antibacterial

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

muscat pharmaceutical trading oman - 500's (10's blister x 50) - tablet - 500mg / tablet - endocrine system-diabetes

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

al ittihad drug store germany - 10's blister - tablet - 500 mg/ tablet - infections-antibacterial

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - metformin hydrochloride 500mg;  ;   - coated tablet - 500 mg - active: metformin hydrochloride 500mg     excipient: magnesium stearate opadry clear oy-29020 povidone water - -treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. -metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents. - adjuvant therapy in insulin dependent diabetes especially if overweight.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - mesalazine 500mg;   - enteric coated tablet - 500 mg - active: mesalazine 500mg   excipient: colloidal silicon dioxide crospovidone hypromellose povidone k90   methacrylic acid - methyl metacrylate copolymer (1:2) iron oxide yellow macrogol 6000   magnesium stearate   microcrystalline cellulose povidone purified talc titanium dioxide triethyl citrate - the treatment of crohn's disease localised to the colon.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 574mg equivalent to amoxycillin 500 mg;  ; potassium clavulanate 149mg equivalent to clavulanic acid 125 mg;   - film coated tablet - 500mg/125mg - active: amoxicillin trihydrate 574mg equivalent to amoxycillin 500 mg   potassium clavulanate 149mg equivalent to clavulanic acid 125 mg   excipient: croscarmellose sodium ethylcellulose hypromellose magnesium stearate microcrystalline cellulose povidone purified talc   purified water titanium dioxide triethyl citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - meclizine hydrochloride 12.5 mg - meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. meclizine hydrochloride tablets are contraindicated in patients with a hypersensitivity to meclizine or any of the inactive ingredients [see adverse reactions (6) and description (11)] . risk summary data from epidemiological studies have not generally indicated a drug-associated risk of major birth defects with meclizine during pregnancy. however, in a published study, an increased incidence of fetal malformations was observed following oral administration of meclizine to pregnant rats during the period of organogenesis, at doses similar to those used clinically. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data human data epidemiologic

United States - English - NLM (National Library of Medicine)

sandoz inc - fluphenazine hydrochloride (unii: zou145w1xl) (fluphenazine - unii:s79426a41z) - fluphenazine hydrochloride 1 mg - fluphenazine hcl is indicated in the management of manifestations of psychotic disorders. fluphenazine hcl has not been shown effective in the management of behavioral complications in patients with mental retardation. phenothiazines are contraindicated in patients with suspected or established subcortical brain damage, in patients receiving large doses of hypnotics, and in comatose or severely depressed states. the presence of blood dyscrasia or liver damage precludes the use of fluphenazine hydrochloride. fluphenazine hcl is contraindicated in patients who have shown hypersensitivity to fluphenazine; cross-sensitivity to phenothiazine derivatives may occur.

Australia - English - Department of Health (Therapeutic Goods Administration)

leo pharma pty ltd - calcipotriol, quantity: 50 microgram/g; betamethasone dipropionate, quantity: 643 microgram/g (equivalent: betamethasone, qty 500 microgram/g) - ointment - excipient ingredients: liquid paraffin; polyoxypropylene-11 stearyl ether; dl-alpha-tocopherol; white soft paraffin; butylated hydroxytoluene - daivobet ointment is indicated for the once daily topical treatment of plaque-type psoriasis vulgaris amenable to topical therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 500 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; hydrogenated castor oil; magnesium stearate; hyprolose; crospovidone; dibasic sodium phosphate; colloidal anhydrous silica; hypromellose - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.